Hodgkin disease/lymphoma: Clinical practice guidelines in oncology™

Richard T. Hoppe, Ranjana Hira Advani, Philip Jay Bierman, Clara D. Bloomfield, Francis Buadi, Benjamin Djulgegovic, Andres Forero, Leo I. Gordon, Francisco J. Hernandez-Ilizaliturri, Mark S. Kaminski, Gena Love, David G. Maloney, Peter M. Mauch, Joseph O. Moore, Russell J. Schilder, Lawrence Weiss, Jane N. Winter, Joachim Yahalom, Andrew D. Zelenetz

Research output: Contribution to journalReview article

27 Citations (Scopus)

Abstract

The management of HD continues to evolve, and the NCCN guidelines have undergone major changes since their inception. Current management programs are based on comprehensive clinical staging followed by combined modality therapy for patients with favorable and intermediate prognosis, or chemotherapy alone for patients with advanced disease. Relapse is uncommon, but secondary management with peripheral stem cell transplantation may be effective. The excellent prognosis for these patients mandates careful long-term follow-up to detect late treatment effects.

Original languageEnglish (US)
Pages (from-to)210-230
Number of pages21
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume4
Issue number3
StatePublished - Mar 1 2006

Fingerprint

Hodgkin Disease
Practice Guidelines
Peripheral Blood Stem Cell Transplantation
Combined Modality Therapy
Guidelines
Recurrence
Drug Therapy
Therapeutics

Keywords

  • Classical HD
  • Combined modality therapy
  • Hodgkin disease
  • Lymphocyte predominance
  • Lymphoma
  • NCCN Clinical Practice Guidelines

ASJC Scopus subject areas

  • Oncology

Cite this

Hoppe, R. T., Advani, R. H., Bierman, P. J., Bloomfield, C. D., Buadi, F., Djulgegovic, B., ... Zelenetz, A. D. (2006). Hodgkin disease/lymphoma: Clinical practice guidelines in oncology™. JNCCN Journal of the National Comprehensive Cancer Network, 4(3), 210-230.

Hodgkin disease/lymphoma : Clinical practice guidelines in oncology™. / Hoppe, Richard T.; Advani, Ranjana Hira; Bierman, Philip Jay; Bloomfield, Clara D.; Buadi, Francis; Djulgegovic, Benjamin; Forero, Andres; Gordon, Leo I.; Hernandez-Ilizaliturri, Francisco J.; Kaminski, Mark S.; Love, Gena; Maloney, David G.; Mauch, Peter M.; Moore, Joseph O.; Schilder, Russell J.; Weiss, Lawrence; Winter, Jane N.; Yahalom, Joachim; Zelenetz, Andrew D.

In: JNCCN Journal of the National Comprehensive Cancer Network, Vol. 4, No. 3, 01.03.2006, p. 210-230.

Research output: Contribution to journalReview article

Hoppe, RT, Advani, RH, Bierman, PJ, Bloomfield, CD, Buadi, F, Djulgegovic, B, Forero, A, Gordon, LI, Hernandez-Ilizaliturri, FJ, Kaminski, MS, Love, G, Maloney, DG, Mauch, PM, Moore, JO, Schilder, RJ, Weiss, L, Winter, JN, Yahalom, J & Zelenetz, AD 2006, 'Hodgkin disease/lymphoma: Clinical practice guidelines in oncology™', JNCCN Journal of the National Comprehensive Cancer Network, vol. 4, no. 3, pp. 210-230.
Hoppe RT, Advani RH, Bierman PJ, Bloomfield CD, Buadi F, Djulgegovic B et al. Hodgkin disease/lymphoma: Clinical practice guidelines in oncology™. JNCCN Journal of the National Comprehensive Cancer Network. 2006 Mar 1;4(3):210-230.
Hoppe, Richard T. ; Advani, Ranjana Hira ; Bierman, Philip Jay ; Bloomfield, Clara D. ; Buadi, Francis ; Djulgegovic, Benjamin ; Forero, Andres ; Gordon, Leo I. ; Hernandez-Ilizaliturri, Francisco J. ; Kaminski, Mark S. ; Love, Gena ; Maloney, David G. ; Mauch, Peter M. ; Moore, Joseph O. ; Schilder, Russell J. ; Weiss, Lawrence ; Winter, Jane N. ; Yahalom, Joachim ; Zelenetz, Andrew D. / Hodgkin disease/lymphoma : Clinical practice guidelines in oncology™. In: JNCCN Journal of the National Comprehensive Cancer Network. 2006 ; Vol. 4, No. 3. pp. 210-230.
@article{515dc42eeb88432b9bc80963737593bf,
title = "Hodgkin disease/lymphoma: Clinical practice guidelines in oncology™",
abstract = "The management of HD continues to evolve, and the NCCN guidelines have undergone major changes since their inception. Current management programs are based on comprehensive clinical staging followed by combined modality therapy for patients with favorable and intermediate prognosis, or chemotherapy alone for patients with advanced disease. Relapse is uncommon, but secondary management with peripheral stem cell transplantation may be effective. The excellent prognosis for these patients mandates careful long-term follow-up to detect late treatment effects.",
keywords = "Classical HD, Combined modality therapy, Hodgkin disease, Lymphocyte predominance, Lymphoma, NCCN Clinical Practice Guidelines",
author = "Hoppe, {Richard T.} and Advani, {Ranjana Hira} and Bierman, {Philip Jay} and Bloomfield, {Clara D.} and Francis Buadi and Benjamin Djulgegovic and Andres Forero and Gordon, {Leo I.} and Hernandez-Ilizaliturri, {Francisco J.} and Kaminski, {Mark S.} and Gena Love and Maloney, {David G.} and Mauch, {Peter M.} and Moore, {Joseph O.} and Schilder, {Russell J.} and Lawrence Weiss and Winter, {Jane N.} and Joachim Yahalom and Zelenetz, {Andrew D.}",
year = "2006",
month = "3",
day = "1",
language = "English (US)",
volume = "4",
pages = "210--230",
journal = "JNCCN Journal of the National Comprehensive Cancer Network",
issn = "1540-1405",
publisher = "Cold Spring Publishing LLC",
number = "3",

}

TY - JOUR

T1 - Hodgkin disease/lymphoma

T2 - Clinical practice guidelines in oncology™

AU - Hoppe, Richard T.

AU - Advani, Ranjana Hira

AU - Bierman, Philip Jay

AU - Bloomfield, Clara D.

AU - Buadi, Francis

AU - Djulgegovic, Benjamin

AU - Forero, Andres

AU - Gordon, Leo I.

AU - Hernandez-Ilizaliturri, Francisco J.

AU - Kaminski, Mark S.

AU - Love, Gena

AU - Maloney, David G.

AU - Mauch, Peter M.

AU - Moore, Joseph O.

AU - Schilder, Russell J.

AU - Weiss, Lawrence

AU - Winter, Jane N.

AU - Yahalom, Joachim

AU - Zelenetz, Andrew D.

PY - 2006/3/1

Y1 - 2006/3/1

N2 - The management of HD continues to evolve, and the NCCN guidelines have undergone major changes since their inception. Current management programs are based on comprehensive clinical staging followed by combined modality therapy for patients with favorable and intermediate prognosis, or chemotherapy alone for patients with advanced disease. Relapse is uncommon, but secondary management with peripheral stem cell transplantation may be effective. The excellent prognosis for these patients mandates careful long-term follow-up to detect late treatment effects.

AB - The management of HD continues to evolve, and the NCCN guidelines have undergone major changes since their inception. Current management programs are based on comprehensive clinical staging followed by combined modality therapy for patients with favorable and intermediate prognosis, or chemotherapy alone for patients with advanced disease. Relapse is uncommon, but secondary management with peripheral stem cell transplantation may be effective. The excellent prognosis for these patients mandates careful long-term follow-up to detect late treatment effects.

KW - Classical HD

KW - Combined modality therapy

KW - Hodgkin disease

KW - Lymphocyte predominance

KW - Lymphoma

KW - NCCN Clinical Practice Guidelines

UR - http://www.scopus.com/inward/record.url?scp=33645933906&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645933906&partnerID=8YFLogxK

M3 - Review article

C2 - 16507269

AN - SCOPUS:33645933906

VL - 4

SP - 210

EP - 230

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

SN - 1540-1405

IS - 3

ER -